FlowMetric Life Sciences, Inc. selected as IsoPlexis Certified Service Provider

DOYLESTOWN, Pa., Aug. 4, 2020 /PRNewswire/ — FlowMetric Life Sciences, Inc., a global leader in Flow Cytometry services, and  IsoPlexis, the leader in functional single-cell proteomics, announce FlowMetric as a Certified Service Provider of the IsoPlexis technology. 

This certification was awarded after FlowMetric met the rigorous training and testing requirements set out by IsoPlexis.  FlowMetric can now provide Single-Cell Functional Proteomic services to its Pharmaceutical and Biotechnology customers to complement its decade-long expertise in developing and validating multi-parameter Flow Cytometry-based approaches for drug development.   

“The FlowMetric team continually looks for new and powerful service offerings for our clients. The IsoPlexis platform delivers state-of-the-art proteomic analysis, enabling us to reveal the true functionality of cells,” said FlowMetric Chief Scientific Officer, Dr. Julie Bick, “Like Flow Cytometry, the IsoPlexis technology has applications across many areas of clinical research and will help our clients identify key biological drivers and ultimately accelerate their scientific research.”

FlowMetric is the only Contract Research Organization (CRO) on the East Coast to offer the menu of IsoPlexis’ IsoCode & CodePlex assays for the study of cancer immunology, inflammation, vaccine development, and cell and gene therapy research.  The IsoPlexis technology provides comprehensive workflows that combine proprietary content and bioinformatic solutions to enable large data sets to be acquired from small sample volumes.

Coupling the IsoPlexis system with multi-parameter Flow Cytometry has the potential to overcome many of the challenges in the research of complex diseases and provide critical data to drive innovation in precision drug discovery. 

Sean Mackay, Chief Executive Officer of IsoPlexis added: “We are very excited to have FlowMetric as our first East Coast Certified Service Provider for the IsoPlexis platform. Our single-cell proteomics platform is capable of providing unique data across a wide range of applications. We look forward to the platform being widely accessible through FlowMetric, enabling more leading research laboratories and institutions to access the cutting-edge functional data needed to accelerate their research.”

About FlowMetric Life Sciences, Inc.
The mission of FlowMetric Life Sciences, Inc. is to improve lives, driven by our dedication to scientific expertise, integrity, innovation, and people.  With laboratories in Doylestown, PA (USA) and Bresso, Italy, FlowMetric is a globally recognized Contract Research Organization providing world-class analytical services and Flow Cytometry capabilities to many of the world’s largest Pharmaceutical and Biotech companies.

About IsoPlexis
IsoPlexis (www.isoplexis.com) is dedicated to accelerating the fight against cancer and a range of the world’s toughest diseases with its uniquely correlative, award-winning single-cell proteomics systems. By revealing unique immune biomarkers in small subsets of cells, we are advancing immunotherapies and targeted therapies to a more highly precise & personalized stage. Our integrated systems, named #1 innovation by the Scientist Magazine & Fierce, are used globally to advance the field of single-cell biology and biomarkers.

View original content to download multimedia:http://www.prnewswire.com/news-releases/flowmetric-life-sciences-inc-selected-as-isoplexis-certified-service-provider-301105171.html

SOURCE FlowMetric

Staff

Recent Posts

The State of HTM, 2025: Report Signals Changing Health Tech Workforce

Biomedical Engineers, Clinical Engineers, Others Weigh in on State of the Health Care IndustryArlington, Virginia--(Newsfile…

43 minutes ago

Standard Process Launches Cultivate, a New Practitioner Symposium Advancing Whole-Food Nutrition and Healthy Aging

Two immersive 2026 events in Seattle and Boston will offer up to 12 CE credits,…

2 hours ago

Vericel Announces Preliminary 2025 Financial Results and Business Updates

Total Revenue Expected to be $276 Million  MACI Revenue Expected to be $239.5 Million Fourth…

2 hours ago

Stroke Experts Challenge “90-Day Recovery” Myth: New Research Shows Patients Need Long-Term Care

Study published by Centre for Neuro Skills researchers in Brain Injury journal argues current insurance…

2 hours ago

Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed® in Community-Based Care

Partnership enables broader adoption of FemaSeed through a trusted community health provider serving a large,…

2 hours ago

IMDX Supports AST and ASHI STAR Working Group’s Call for Decentralized Transplant Monitoring

American Journal of Transplantation position paper also highlights value of absolute quantification of dd-cfDNA as…

2 hours ago